Juan Fernando Agudelo Uribe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Juan Fernando Agudelo Uribe has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Rafael Correa Velasquez
Clinica CardioVID, Medellín, Colombia; Universidad San Pablo-CEU, CEU Universities, Madrid, Spain
2 shared publications A. John Camm
City St George's University of London London UK
1 shared publication- Alex Pacheco-Bouthillier
Inst Cardiovasc Minima Invas, Guadalajara, Mexico
1 shared publication - Alicia Sale
Medtronic, Minneapolis, MN USA
1 shared publication - Andrés David Aranzazu-Ceballos
Universidad Pontificia Bolivariana
1 shared publication Anita Holz
Milestone Pharmaceuticals Charlotte NC USA
1 shared publication
Latest Publications
- Open Access
- 15 July 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4)
Fractionated Atrial Electrograms Identify Sites of Autonomic Responses During Pulmonary Vein Isolation: Insights for Cardioneuroablation
Background: Cardioneuroablation (CNA) targets atrial ganglionated plexuses (GP) to treat vagally mediated bradyarrhythmias. Automated electrogram fractionation mapping has been proposed as a surrogate tool for GP localization, but optimal parameter settings remain undefined. We aimed to systematically evaluate automated fractionation mapping parameters and their association with autonomic responses during ablation. Methods: Data from 26 patients were analyzed, including 12 patients undergoing atrial fibrillation (AF) ablation in sinus rhythm and 14 patients undergoing CNA. Using high‐density electroanatomical mapping, three predefined values were tested for each fractionation parameter—signal width, refractoriness, and amplitude threshold—yielding 27 automated configurations. A purely anatomical localization strategy was also evaluated. In the AF cohort, all configurations were systematically assessed, generating 336 fractionation maps and 870 ablation sites. Autonomic response during radiofrequency delivery was defined as an absolute RR interval change > 10%. Selected high‐performing configurations were subsequently evaluated in the CNA cohort (614 ablation sites). Results: In the AF cohort, 25 of 27 configurations showed a significant association with autonomic response. After Bonferroni correction, 15 configurations remained significant. The configuration with signal width 15 ms, refractoriness 25 ms, and amplitude threshold 0.05 mV demonstrated the highest sensitivity, although several configurations showed comparable performance. When evaluated in the CNA cohort, this configuration yielded a sensitivity of 74.1% and specificity of 73.9%. Conclusions: This pilot study provides a reproducible framework for evaluating automated fractionation mapping parameters associated with autonomic responses during CNA. The findings support biologically plausible parameter–performance relationships and identify parameter ranges potentially suitable for procedural use.
- 15 July 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (4)
Open AccessFractionated Atrial Electrograms Identify Sites of Autonomic Responses During Pulmonary Vein Isolation: Insights for Cardioneuroablation
Background: Cardioneuroablation (CNA) targets atrial ganglionated plexuses (GP) to treat vagally mediated bradyarrhythmias. Automated electrogram fractionation mapping has been proposed as a surrogate tool for GP localization, but optimal parameter settings remain undefined. We aimed to systematically evaluate automated fractionation mapping parameters and their association with autonomic responses during ablation. Methods: Data from 26 patients were analyzed, including 12 patients undergoing atrial fibrillation (AF) ablation in sinus rhythm and 14 patients undergoing CNA. Using high‐density electroanatomical mapping, three predefined values were tested for each fractionation parameter—signal width, refractoriness, and amplitude threshold—yielding 27 automated configurations. A purely anatomical localization strategy was also evaluated. In the AF cohort, all configurations were systematically assessed, generating 336 fractionation maps and 870 ablation sites. Autonomic response during radiofrequency delivery was defined as an absolute RR interval change > 10%. Selected high‐performing configurations were subsequently evaluated in the CNA cohort (614 ablation sites). Results: In the AF cohort, 25 of 27 configurations showed a significant association with autonomic response. After Bonferroni correction, 15 configurations remained significant. The configuration with signal width 15 ms, refractoriness 25 ms, and amplitude threshold 0.05 mV demonstrated the highest sensitivity, although several configurations showed comparable performance. When evaluated in the CNA cohort, this configuration yielded a sensitivity of 74.1% and specificity of 73.9%. Conclusions: This pilot study provides a reproducible framework for evaluating automated fractionation mapping parameters associated with autonomic responses during CNA. The findings support biologically plausible parameter–performance relationships and identify parameter ranges potentially suitable for procedural use.
- 10 April 2026
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 12 (8) , 1906-1917
New Criteria to Demonstrate Entrainment and Macro–Re-Entry in Atrial Tachycardias
- 10 April 2026
- Published by Elsevier in JACC: Clinical Electrophysiology
- Vol. 12 (8) , 1906-1917
New Criteria to Demonstrate Entrainment and Macro–Re-Entry in Atrial Tachycardias
- Open Access
- 11 September 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (11) , 2990-3003
Etripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE‐303 Open‐Label Study
Introduction: Etripamil is a fast‐acting intranasally self‐administered calcium‐channel blocker developed for termination of paroxysmal supraventricular tachycardia (PSVT). Prior studies have demonstrated safety and efficacy of etripamil for PSVT termination following an initial medically supervised test dose during sinus rhythm. NODE‐303 is an open‐label, single‐arm study that evaluated etripamil for multiple, at‐home PSVT episodes, without test dose before first use. Methods: Patients applied an ECG monitor at symptom onset and self‐administered etripamil (70 mg) if a vagal maneuver was unsuccessful. ECG monitoring occurred for ≥ 1 h following study drug administration. A repeat 70‐mg dose was introduced during the study for symptoms persisting 10 min after the first dose. Safety measures included treatment‐emergent adverse events (TEAEs) and ECG arrhythmia‐surveillance. Efficacy measures were captured for PSVT termination during treatment of each of the multiple episodes. Results: 1054 perceived PSVT episodes were etripamil‐treated in 503 of 1116 patients enrolled. TEAEs within 24 h were mostly mild or moderate and localized: 30.2% of patients experienced nasal discomfort, nasal congestion (13.9%), rhinorrhea (13.1%), epistaxis (7.4%). TEAE frequencies decreased across multiple PSVT episodes and were similar for single versus repeat doses. For first PSVT episodes, 70.5% of patients converted to sinus rhythm by 60 min post etripamil (median time to conversion = 18.3 min [14.2–25.6]). Conversion in earlier episodes was consistently predictive of conversion in subsequent episodes. Conclusions: Etripamil nasal spray self‐administered in a real‐world setting was well tolerated, effective, and had a consistent safety profile as a single‐ or repeat‐dose regimen across multiple PSVT episodes. Trial Registration: ClinicalTrials.gov NCT04072835
- 11 September 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (11) , 2990-3003
Open AccessEtripamil Nasal Spray for Recurrent Paroxysmal Supraventricular Tachycardia Conversion: Results From the NODE‐303 Open‐Label Study
Introduction: Etripamil is a fast‐acting intranasally self‐administered calcium‐channel blocker developed for termination of paroxysmal supraventricular tachycardia (PSVT). Prior studies have demonstrated safety and efficacy of etripamil for PSVT termination following an initial medically supervised test dose during sinus rhythm. NODE‐303 is an open‐label, single‐arm study that evaluated etripamil for multiple, at‐home PSVT episodes, without test dose before first use. Methods: Patients applied an ECG monitor at symptom onset and self‐administered etripamil (70 mg) if a vagal maneuver was unsuccessful. ECG monitoring occurred for ≥ 1 h following study drug administration. A repeat 70‐mg dose was introduced during the study for symptoms persisting 10 min after the first dose. Safety measures included treatment‐emergent adverse events (TEAEs) and ECG arrhythmia‐surveillance. Efficacy measures were captured for PSVT termination during treatment of each of the multiple episodes. Results: 1054 perceived PSVT episodes were etripamil‐treated in 503 of 1116 patients enrolled. TEAEs within 24 h were mostly mild or moderate and localized: 30.2% of patients experienced nasal discomfort, nasal congestion (13.9%), rhinorrhea (13.1%), epistaxis (7.4%). TEAE frequencies decreased across multiple PSVT episodes and were similar for single versus repeat doses. For first PSVT episodes, 70.5% of patients converted to sinus rhythm by 60 min post etripamil (median time to conversion = 18.3 min [14.2–25.6]). Conversion in earlier episodes was consistently predictive of conversion in subsequent episodes. Conclusions: Etripamil nasal spray self‐administered in a real‐world setting was well tolerated, effective, and had a consistent safety profile as a single‐ or repeat‐dose regimen across multiple PSVT episodes. Trial Registration: ClinicalTrials.gov NCT04072835
- 10 June 2025
- Published by Elsevier in Progress in Pediatric Cardiology
- Vol. 78
Transcatheter ablation of incessant ectopic atrial tachycardia in a patient with intracardiac rhabdomyomas
- 10 June 2025
- Published by Elsevier in Progress in Pediatric Cardiology
- Vol. 78
Transcatheter ablation of incessant ectopic atrial tachycardia in a patient with intracardiac rhabdomyomas
- 2 September 2024
- Published by Medwave Estudios Limitada in Medwave
- Vol. 24 (08) , e2918
Electrophysiology lab efficiency using cryoballoon for pulmonary vein isolation in Latin America: A sub-analysis of the Cryo Global Registry Study
Objective Cryoballoon ablation for pulmonary vein isolation is a time-efficient procedure that can alleviate stress on electrophysiology lab resources. This analysis modeled the impact of cryoballoon ablation on electrophysiology lab operation using data from Latin America. Methods Data from centers in Argentina, Mexico, Colombia, and Chile of the were used as inputs for an electrophysiology lab efficiency simulation model. The model used the assumption that either two (today’s electrophysiology lab operations) or three (including electrophysiology lab operational changes) cryoballoon ablation procedures could be performed per day. The endpoints were the percentage of days that resulted in 1) overtime and 2) time left for an extra non-ablation electrophysiology procedure. Results Data from a total of 232 procedures from six Latin American centers were included in the analysis. The average electrophysiology lab occupancy time for all procedures in Latin America was 132 ± 62 minutes. In the Current Scenario (two procedures per day), 7.4% of simulated days resulted in overtime, and 81.4% had enough time for an extra electrophysiology procedure. In the Enhanced Productivity Scenario (three procedures per day), 16.4% of days used overtime, while 67.4% allowed time for an extra non-ablation electrophysiology procedure. Conclusions Using real-world, Latin American-specific data, we found that with operational changes, three ablation procedures could feasibly be performed daily, leaving time for an extra electrophysiology procedure on more than half of days. Thus, use of cryoballoon ablation is an effective tool to enhance electrophysiology lab efficiency in resource-constrained regions such as Latin America.
- 2 September 2024
- Published by Medwave Estudios Limitada in Medwave
- Vol. 24 (08) , e2918
Electrophysiology lab efficiency using cryoballoon for pulmonary vein isolation in Latin America: A sub-analysis of the Cryo Global Registry Study
Objective Cryoballoon ablation for pulmonary vein isolation is a time-efficient procedure that can alleviate stress on electrophysiology lab resources. This analysis modeled the impact of cryoballoon ablation on electrophysiology lab operation using data from Latin America. Methods Data from centers in Argentina, Mexico, Colombia, and Chile of the were used as inputs for an electrophysiology lab efficiency simulation model. The model used the assumption that either two (today’s electrophysiology lab operations) or three (including electrophysiology lab operational changes) cryoballoon ablation procedures could be performed per day. The endpoints were the percentage of days that resulted in 1) overtime and 2) time left for an extra non-ablation electrophysiology procedure. Results Data from a total of 232 procedures from six Latin American centers were included in the analysis. The average electrophysiology lab occupancy time for all procedures in Latin America was 132 ± 62 minutes. In the Current Scenario (two procedures per day), 7.4% of simulated days resulted in overtime, and 81.4% had enough time for an extra electrophysiology procedure. In the Enhanced Productivity Scenario (three procedures per day), 16.4% of days used overtime, while 67.4% allowed time for an extra non-ablation electrophysiology procedure. Conclusions Using real-world, Latin American-specific data, we found that with operational changes, three ablation procedures could feasibly be performed daily, leaving time for an extra electrophysiology procedure on more than half of days. Thus, use of cryoballoon ablation is an effective tool to enhance electrophysiology lab efficiency in resource-constrained regions such as Latin America.